ES2029829T3 - Un procedimiento para la preparacion de compuestos antihipercolesterolemicos. - Google Patents

Un procedimiento para la preparacion de compuestos antihipercolesterolemicos.

Info

Publication number
ES2029829T3
ES2029829T3 ES198787300544T ES87300544T ES2029829T3 ES 2029829 T3 ES2029829 T3 ES 2029829T3 ES 198787300544 T ES198787300544 T ES 198787300544T ES 87300544 T ES87300544 T ES 87300544T ES 2029829 T3 ES2029829 T3 ES 2029829T3
Authority
ES
Spain
Prior art keywords
procedure
preparation
compounds
hypercholesterolemic compounds
hypercholesterolemic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787300544T
Other languages
English (en)
Inventor
Robert L. Smith
Gerald E. Stokker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2029829T3 publication Critical patent/ES2029829T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE DESCRIBEN NUEVOS INHIBIDORES DE LA 3-HIDROXI-3- METIL-GLUTARIL-COENZIMA A(HMG-COA)REDUCTASA QUE SON UTILES COMO AGENTES ANTIHIPERCOLESTEROLEMICOS Y ESTAN REPRESENTADOS POR LAS SIGUIENTES FORMULAS ESTRUCTURALES (I) Y (II). SE DESCRIBEN TAMBIEN LAS SALES FARMACOLOGICAMENTE ACEPTABLES DE LOS COMPUESTOS (II) EN DONDE Z ES HIDROGENO.
ES198787300544T 1986-01-31 1987-01-22 Un procedimiento para la preparacion de compuestos antihipercolesterolemicos. Expired - Lifetime ES2029829T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/824,900 US4772626A (en) 1986-01-31 1986-01-31 Antihypercholesterolemic compounds

Publications (1)

Publication Number Publication Date
ES2029829T3 true ES2029829T3 (es) 1992-10-01

Family

ID=25242603

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787300544T Expired - Lifetime ES2029829T3 (es) 1986-01-31 1987-01-22 Un procedimiento para la preparacion de compuestos antihipercolesterolemicos.

Country Status (7)

Country Link
US (1) US4772626A (es)
EP (1) EP0232997B1 (es)
JP (1) JPS62190144A (es)
AT (1) ATE56715T1 (es)
DE (1) DE3764967D1 (es)
DK (1) DK51087A (es)
ES (1) ES2029829T3 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855321A (en) * 1986-01-31 1989-08-08 Merck & Co., Inc. Antihypercholesterolemic compounds
US5169976A (en) * 1987-11-25 1992-12-08 Pfizer Inc. N-(biphenylmethyl)-3-hydroxyglutaramic acid and derivatives as hypocholesterolemic agents
US5001144A (en) * 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US5001128A (en) * 1987-12-21 1991-03-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. HMG-COA reductase inhibitors
US4900754A (en) * 1987-12-21 1990-02-13 Rorer Pharmaceutical Corp. HMG-COA reductase inhibitors
US4939143A (en) * 1987-12-21 1990-07-03 Rorer Pharmaceutical Corporation Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US4904691A (en) * 1987-12-21 1990-02-27 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
US4863957A (en) * 1987-12-21 1989-09-05 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
US4876280A (en) * 1988-03-10 1989-10-24 Sandoz Pharm. Corp. Arylcyclohexane and arylcyclohexene analogs of mevalonolactone derivatives and their use
DE3818570A1 (de) * 1988-06-01 1989-12-21 Boehringer Mannheim Gmbh Neue 6-substituierte-4-hydroxy-tetrahydro-pyran -2-on-derivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
NZ230121A (en) * 1988-08-29 1993-08-26 Squibb & Sons Inc Pyridine and quinoline terminal groups for hmg-coenzyme a reductase inhibitors and pharmaceutical compositions for lowering blood serum cholesterol levels
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
DE3909378A1 (de) * 1989-03-22 1990-09-27 Bayer Ag Substituierte biphenyle
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
EP0445827B1 (en) * 1990-03-07 1996-09-25 Fujirebio Inc. 4-Hydroxytetrahydropyran-2-one derivatives useful as cholesterol and lipid reducing agents
WO1991013616A1 (en) * 1990-03-08 1991-09-19 Rorer International (Overseas) Inc. NOVEL HMG-CoA REDUCTASE INHIBITORS
US5089523A (en) * 1990-05-11 1992-02-18 E. R. Squibb & Sons, Inc. Fluorinated derivatives of mevinic acids
JP5566284B2 (ja) * 2007-05-29 2014-08-06 エボニック デグサ ゲーエムベーハー 活性化卑金属触媒
WO2019076269A1 (zh) 2017-10-16 2019-04-25 清华大学 甲羟戊酸通路抑制剂及其药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4459422A (en) * 1979-08-17 1984-07-10 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4567289A (en) * 1979-08-17 1986-01-28 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis

Also Published As

Publication number Publication date
US4772626A (en) 1988-09-20
DK51087A (da) 1987-08-01
ATE56715T1 (de) 1990-10-15
DE3764967D1 (de) 1990-10-25
JPS62190144A (ja) 1987-08-20
EP0232997B1 (en) 1990-09-19
EP0232997A1 (en) 1987-08-19
DK51087D0 (da) 1987-01-30

Similar Documents

Publication Publication Date Title
ES2029829T3 (es) Un procedimiento para la preparacion de compuestos antihipercolesterolemicos.
ES2000842A6 (es) Un procedimiento para la preparacion de analogos semisinteticos de compactina y mevinolina
EE03194B1 (et) Ühendid, nende kasutamine magustavate toimeainetena ja nende valmistamise meetod
ES2019899T4 (es) Procedimiento para preparar trans-6-6(2-3(3-o 4-carboxamido-sustituido-pirrol-1-il)-alquil)-4-hidroxipiran-2-onas con actividad inhibidora de la sintesis de colesterol.
DK354189D0 (da) Fremgangsmaade til lactonisering af mevinsyreforbindelser
MX9207152A (es) Composiciones farmaceuticas estabilizadas que comprenden un compuesto inhibidor de la hmg-coa reductasa y metodo para su preparacion.
ES2063097T3 (es) Inhibidor de la glicosidasa salbostatina, procedimiento para su preparacion y su empleo.
ES2009919A6 (es) Procedimiento para preparar inhibidores de hmg-coa-reductasa que contienen fosforo y nuevos compuestos intermedios.
EA200000094A1 (ru) Способ получения замещенного пергидроизоиндола
AR006058A1 (es) Procedimientos para preparar compuestos de dicianoacetato y de 1,2-pirazol-5-amino-3-substituido
EP0577040A3 (es)
EP0245003A3 (en) Antihypercholesterolemic compounds
RU94027686A (ru) Производные ксантина, способ их получения и содержащая их фармацевтическая композиция
IL90781A0 (en) 5-oxygenated hmg-coa reductase inhibitors and pharmaceutical compositions containing them
EP0353607A3 (en) Non-linear optical device
EP0245004A3 (en) Antihypercholesterolemic compounds
TR199802456T2 (xx) Yeni pirol t�revleri.
ES550742A0 (es) Un procedimiento para la preparacion de una octahidroindo- lizina
DK0640092T3 (da) Fremgangsmåde til fremstilling af ribonucleotid-reduktaseinhibitorer
FI953994A (fi) Menetelmä (-)-N-metyyli-N-(4-(4-fenyyli-4-asetyyliaminopiperidiini-1-yl)-2-(3,4-diklorofenyyli)butyyli)bentsamidi ja sen farmaseuttisesti hyväksyttäviä suoloja
AU7500187A (en) Substituted isoquinoline derivatives and anti-ulcer agents
DK0707587T3 (da) Farmakologisk aktive enantiomerer
EP0204287A3 (en) Process for the preparation of hmg-coa reductase inhibitors with a 3,5-dihydroxypentanoate subunit
DE69314929T2 (de) Benzolderivate
ES2113382T3 (es) Derivados de azetidinona y procedimiento para producir derivados de azetidinona y cefalosporina.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 232997

Country of ref document: ES